Molecular and in silico investigation of a novel ECHS1 gene mutation in a consanguine family with short-chain enoyl-CoA hydratase deficiency and Mt-DNA depletion: effect on trimer assembly and catalytic activity.
Marwa MaalejLamia SfaihiOlfa-Alila FersiBoudour KhabouMarwa AmmarRahma FelhiMarwa KharratJihen ChouchenThouraya KammounAbdelaziz TliliFaiza FakhfakhPublished in: Metabolic brain disease (2024)
Short-chain enoyl-CoA hydratase deficiency (ECHS1D) is a rare congenital metabolic disorder that follows an autosomal recessive inheritance pattern. It is caused by mutations in the ECHS1 gene, which encodes a mitochondrial enzyme involved in the second step of mitochondrial β-oxidation of fatty acids. The main characteristics of the disease are severe developmental delay, regression, seizures, neurodegeneration, high blood lactate, and a brain MRI pattern consistent with Leigh syndrome. Here, we report three patients belonging to a consanguineous family who presented with mitochondrial encephalomyopathy. Whole-exome sequencing revealed a new homozygous mutation c.619G > A (p.Gly207Ser) at the last nucleotide position in exon 5 of the ECHS1 gene. Experimental analysis showed that normal ECHS1 pre-mRNA splicing occurred in all patients compared to controls. Furthermore, three-dimensional models of wild-type and mutant echs1 proteins revealed changes in catalytic site interactions, conformational changes, and intramolecular interactions, potentially disrupting echs1 protein trimerization and affecting its function. Additionally, the quantification of mtDNA copy number variation in blood leukocytes showed severe mtDNA depletion in all probands.
Keyphrases
- copy number
- mitochondrial dna
- end stage renal disease
- fatty acid
- oxidative stress
- chronic kidney disease
- ejection fraction
- genome wide
- newly diagnosed
- prognostic factors
- gene expression
- computed tomography
- hydrogen peroxide
- intellectual disability
- contrast enhanced
- molecular dynamics simulations
- molecular docking
- smoking cessation
- peripheral blood
- multiple sclerosis
- transcription factor
- duchenne muscular dystrophy
- replacement therapy